Atlas Trials

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

Clinical trial NCT00489385 · COMPLETED

Trial details

NCT number
NCT00489385
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HIV InfectionsHCV
Start date
2007-06-18
Primary completion
2011-03-15
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.